## AFL: Aflac Incorporated - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Caution: momentum weakening (-2.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($106.75)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. 14 Best Dividend Growth Stocks to Buy and Hold in 2026**
- Source: Insider Monkey | 20260106T172100 | Bullish | Relevance: 100%
- This article is part of a list detailing the best dividend growth stocks to buy and hold in 2026, focusing on Aflac Incorporated (NYSE:AFL). It highlights Aflac's dividend growth rate, recent analyst ratings, and discusses a recent cyberattack that exposed customer data. Despite the security breach, Aflac is monitoring for fraudulent activity and continues to provide financial protection products.

**2. Aflac Stock Holds Its Ground: Solid Dividend Player Amid A Quiet Tape**
- Source: AD HOC NEWS | 20260107T140916 | Bullish | Relevance: 100%
- Aflac Inc. (AFL) stock has shown resilience, trading near its 52-week highs, positioning it as a defensive dividend player despite a quiet news cycle. The insurer's consistent performance and capital returns have attracted income-focused investors, with analysts maintaining a constructive outlook and modest price targets. Aflac's strategy, rooted in supplemental insurance and strong capital management, suggests continued steady growth and shareholder returns.

**3. Aflac Selects CyEx's Medical Shield to Provide Medical Fraud Protection for Individuals Impacted by Data Breach**
- Source: PR Newswire | 20260106T140814 | Somewhat-Bullish | Relevance: 100%
- Aflac has chosen CyEx's Medical Shield to provide medical fraud protection for 22.65 million individuals affected by a recent cyberattack. Recognizing the sensitive personal health information potentially exposed, Aflac opted for Medical Shield's comprehensive monitoring and insurance coverage, going beyond standard credit monitoring. This decision highlights Aflac's commitment to robust protection against the growing threat of medical identity theft.

**4. Robeco Institutional Asset Management B.V. Has $176.29 Million Stock Position in Aflac Incorporated $AFL**
- Source: MarketBeat | 20260106T120352 | Somewhat-Bullish | Relevance: 100%
- Robeco Institutional Asset Management B.V. reduced its stake in Aflac Incorporated (NYSE:AFL) by 4.6% in the third quarter, now holding 1,578,210 shares worth $176.29 million. Other institutional investors have also adjusted their positions, and 67.44% of Aflac's stock is institutionally owned. Analysts have issued varied ratings, with a consensus "Hold" and a target price of $110.92, while company insiders have recently sold shares.

**5. Aflac Incorporated to Release Fourth Quarter Results and CFO Video Update on February 4, 2026 and Host Webcast on February 5, 2026**
- Source: Yahoo Finance UK | 20260105T210807 | Neutral | Relevance: 100%
- Aflac Incorporated announced it will release its fourth-quarter 2025 financial results after the market closes on Wednesday, February 4, 2026. This release will be accompanied by a financial update video from CFO Max BrodÃ©n on the company's Investor Relations website. Additionally, Aflac will host a webcast conference call on Thursday, February 5, 2026, at 8:00 a.m. ET, where company leaders will discuss results and answer questions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | JP Morgan | $105 | $101 | +4% |
| 2025-12-30 | Raymond James | $119 | $110 | +8% |
| 2025-12-22 | TD Cowen | $102 | $100 | +2% |
| 2025-12-16 | Mizuho | $104 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | JP Morgan | main | Neutral |
| 2025-12-30 | Raymond James | main | Outperform |
| 2025-12-22 | TD Cowen | main | Hold |
| 2025-12-16 | Mizuho | init | Underperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.27M) |
| Sells | 10 ($2.69M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Japan Post Holdings : 10.0% (0.0%)
- Vanguard Group Inc: 9.6% (-0.8%)
- Blackrock Inc.: 7.4% (+0.1%)
- State Street Corpora: 4.6% (+0.1%)
- Wells Fargo & Compan: 2.1% (-24.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Quality metrics strong (margin 24%). Balance sheet: strong liquidity (48.2x). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $58.9B |
| Beta | 0.66 |
| 52W Range | $96.95 - $115.84 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 14.9 |
| Current P/E | 14.4 |
| YoY Growth | -3.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 1.1% to -0.9% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 49. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.93% (CS: 42) | Neutral |
| RSI_14 | 49.1 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.030x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $110.19
- **Stop Loss:** $106.75 (3.1% risk)
- **Target:** $117.07 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 290
- **Position Value:** $31,955.10
- **Portfolio %:** 31.96%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-04 (Est: $1.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $2.49 | +40.2% |
| 2025Q2 | $1.71 | $1.78 | +4.3% |
| 2025Q1 | $1.67 | $1.66 | -0.8% |
| 2024Q4 | $1.62 | $1.56 | -3.5% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*